JonesTrading Maintains Buy Rating and $82 Price Target for Rapport Therapeutics
JonesTrading analyst Justin Walsh has reaffirmed a 'Buy' rating and a $82 price target for Rapport Therapeutics, Inc. (NASDAQ: RAPP).
Stocks · News reference
Rapport Therapeutics announced the pricing of its previously proposed public offerings, totaling approximately $175 million in common stock and $150 million in convertible senior notes.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
JonesTrading analyst Justin Walsh has reaffirmed a 'Buy' rating and a $82 price target for Rapport Therapeutics, Inc. (NASDAQ: RAPP).
Following the company's third-quarter earnings report, several financial institutions, including UBS and Guggenheim, adjusted their price targets for Rapport Therapeutics.
Rapport Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $40.2 million and providing updates on its clinical pipeline, including the RAP-219 program.
Filed: 2026-11-04 AccNo: 0001193125-26-446202 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits